#Sweden #Vienna #Sobi #C3G #VALIANT Study

Sobi's Scientific Showcase at ERA 2025

Sobi® (STO: SOBI) is set to make a significant impact at the upcoming ERA congress, taking place in Vienna from June 4 to June 7, 2025. The biopharmaceutical company will present a total of eight research contributions, which include six oral presentations and two posters. This year’s congress comes with the exciting news that two of Sobi's abstracts have been recognized among the top 10 abstracts at the ERA 2025 by expert reviewers of the Paper Selection Committee.

One of the highlights of the event will be the presentation of 52-week results from the open-label period (OLP) of the VALIANT Phase 3 study. This particular data will be shared for the very first time during an oral presentation by Professor Fadi Fakhouri from Lausanne University Hospital on June 6, 2025, at 15:00 CEST in a session titled "Innovative Kidney Trials."

Lydia Abad-Franch, MD, MBA, who is the Head of Research, Development, and Medical Affairs at Sobi, stated, "The substantial number of oral presentations reflects the crucial importance of the data being generated through our research. It aims to enhance treatments for rare kidney conditions."

Key Presentations at ERA 2025

Several critical studies will be presented, emphasizing various aspects of kidney health:

1. Healthcare Provider Perspectives on C3G and IC-MPGN - This thematic analysis will focus on the unmet medical needs and care pathways in affected patients. Carly Rich will present this poster on June 5 during the Glomerular and Tubulo-Interstitial Diseases session.

2. Effect of Pegcetacoplan Treatment - Antonio Mastrangelo will discuss the treatment effect of pegcetacoplan in patients exhibiting nephrotic range proteinuria in an oral presentation slated for June 6.

3. Adolescent Treatment Insights - Mastrangelo will also present findings related to adolescents undergoing treatment with pegcetacoplan during the same session.

4. Clinical Responses in C3G and IC-MPGN Patients - The data reveals significant responses to pegcetacoplan treatment with and without concurrent immunosuppression, which will be discussed by David Kavanagh.

5. Association Between Proteinuria and Clinical Endpoints - Fernando Caravaca-Fontán will present results from a consensus of European experts assessing meaningful clinical endpoints associated with protein levels in C3G and IC-MPGN patients.

6. Sustained Efficacy Overview - Professor Fadi Fakhouri will share insights on 52-week results from the VALIANT trial, emphasizing the sustained efficacy of pegcetacoplan.

7. Post-Transplant Treatment - Michiel Oosterveld will present focused findings on pegcetacoplan's effectiveness for recurrent C3G or primary IC-MPGN post-transplant.

8. Halting Disease Progression - Finally, Daniel Gale will showcase pivotal results indicating that pegcetacoplan appears to stop disease progression in subjects, drawing from comprehensive insights from the Phase 3 VALIANT study.

About the VALIANT Study

The VALIANT Phase 3 study (NCT05067127) is the largest trial conducted on C3G and primary IC-MPGN, involving 124 patients aged 12 and above. This randomized, placebo-controlled trial evaluated the safety and efficacy of pegcetacoplan, involving subcutaneous administration twice weekly. Following 26 weeks of randomized control, the subsequent 26 weeks involved an open-label period where all patients received the treatment. The primary measure of success looked into the change in urine protein-to-creatinine ratio at week 26 versus baseline levels.

Final Thoughts

Sobi stands at the forefront of advancing treatments for rare kidney conditions, and participation in the ERA 2025 congress only exemplifies their commitment to impactful research and innovation. With this strong showing of new data, Sobi aims to reshape the understanding and management of complex kidney diseases, while contributing greatly to the discourse in nephrology at this esteemed congress.

For more information about Sobi and their advancements, you can visit sobi.com.